Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

June 12, 2023

Study Completion Date

June 12, 2023

Conditions

Migraine Without Aura

Interventions

DRUG

Levcromakalim

Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes

OTHER

Placebo

Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes

Trial Locations (1)

Danish Headache Center, Copenhagen